Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation life-changing cancer immunotherapies with the identification of unique and ...

G2G Bio partners with Boehringer Ingelheim to develop long-lasting injectable drug G2G Bio collaborates with Boehringer Ingelheim to innovate in injectable drug development ...

Learn how turkey producers in the U.S. will soon be able to vaccinate their birds to prevent the highly contagious disease.

Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim India and EMRI Green Health Services partner to improve stroke care through specialized training and ...

The Campaign will Donate Millions of Meals and Thousands of Doses of NexGard® PLUS (afoxolaner, moxidectin, and pyrantel ...